Probiotics: The Path to Better Digestive Health through Quality Clinical Trials
DuPont Nutrition & Health
Breaking News on Supplements & Nutrition - North AmericaEU edition
Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.
Spotlight
  Connecticut State Senate passes GMO labeling legislationThe legislative pressure on mandatory GMO labeling continues to build, at least on the state front, as... |
 Warning letter gives look at how FDA views supplement-beverage divideAmong recent warning letters sent by the US Food and Drug Administration to supplement manufacturers one stood... |
 Optimal synbiotics – new study unlocks the ideal pre- and probiotic combinationsA team of researchers may have taken a large step towards designing the optimal synbiotics for gut... |
  Live from VitaFoods 2013GMO ingredients can form part of Omega-3 supply picture, GOED chief saysAdam Ismail Executive Director, GOED |
 Association to hold seminar on 'The Non-GMO Future'UNPA: ‘We sense that the GMO issue is substantially more significant than dietary supplement companies think’Dietary supplement manufacturers need to consider the implications of possible GMO labeling initiatives, with the issue more... |
 CSPI to Bayer: Fix your One A Day claims or we’ll start a lawsuitThe Center for Science in the Public Interest (CSPI) is threatening litigation against Bayer for alleged “deceptive practices... |
 Trade associations urge FDA to issue revised draft guidance on NDI ingredient identityThe five associations representing the dietary supplement industry have asked the Food and Drug Administration (FDA) to... |
Further comment on dubious study
As I stated a week ago in response to the recently released study on resveratrol, the fault here is with the study design and protocol itself, not the resveratrol used in the study. The dosage used in this study was ridiculously low, compared to all earlier studies. In the case of the successful Albert Einstein Medical School study and the more recent Florida Pharmacology School study the dosages were approximately 10 to 20 times this amount. This dosage is consistent with the supplements used in those trials, specifically biotivia transmax and bioforte, which are readily available without a prescription. Using a dosage of only 75mg was tantamount to giving a heart attack victim one aspirin.
In all previous studies on actual type 2 diabetic patients or those suffering impaired glucose tolerance, a sign of impending diabetes, resveratrol was extremely effective in improving glucose tolerance, enhancing metabolic function and blocking the onset of diabetes.
As a cell biologist who has been involved in several human clinical trials of transmax and bioforte resveratrol against diabetes, I can only imagine that this study was designed by a pharmaceutical company to fail intentionally. The pharmas are clearly aware of the potential of resveratrol to cut into their sales of Metformin, a multi-billion dollar earner for the drug companies, and are on a campaign to discredit the compound.
As a researcher I question why the clinicians in this study would select as subjects women who have no issues with glucose tolerance, who were non-obese, and who did not exhibit signs of diabetes. This is equivalent to testing a compound designed to treat cancer on a group of subjects none of whom has cancer. Again, we see a troubling signal of possible pharma involvement.
Posted by James Betz
01 November 2012 | 08h40